NeuroSense Therapeutics NRSN Stock
NeuroSense Therapeutics Price Chart
NeuroSense Therapeutics NRSN Financial and Trading Overview
| NeuroSense Therapeutics stock price | 0.77 USD |
| Previous Close | 0.8 USD |
| Open | 0.83 USD |
| Bid | 0.61 USD x 200 |
| Ask | 1 USD x 200 |
| Day's Range | 0.77 - 0.9 USD |
| 52 Week Range | 0.63 - 2.35 USD |
| Volume | 321.11K USD |
| Avg. Volume | 146.61K USD |
| Market Cap | 28.48M USD |
| Beta (5Y Monthly) | 1.541 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.44 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.5 USD |
NRSN Valuation Measures
| Enterprise Value | 27.9M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.9621951 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.52 |
Trading Information
NeuroSense Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.541 |
| 52-Week Change | -65.84% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 2.35 USD |
| 52 Week Low | 0.63 USD |
| 50-Day Moving Average | 0.79 USD |
| 200-Day Moving Average | 0.94 USD |
NRSN Share Statistics
| Avg. Volume (3 month) | 146.61K USD |
| Avg. Daily Volume (10-Days) | 207.93K USD |
| Shares Outstanding | 36.1M |
| Float | 21.4M |
| Short Ratio | 2.72 |
| % Held by Insiders | 32.30% |
| % Held by Institutions | 1.07% |
| Shares Short | 369.63K |
| Short % of Float | 1.32% |
| Short % of Shares Outstanding | 1.01% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -247.30% |
| Return on Equity (ttm) | -2174.97% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -11069000 USD |
| Net Income Avi to Common (ttm) | -11125000 USD |
| Diluted EPS (ttm) | -0.44 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 166K USD |
| Total Cash Per Share (mrq) | 0.005 USD |
| Total Debt (mrq) | 170K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.309 |
| Book Value Per Share (mrq) | -0.048 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7671000 USD |
| Levered Free Cash Flow (ttm) | -3869125 USD |
Profile of NeuroSense Therapeutics
| Country | United States |
| State | N/A |
| City | Herzliya |
| Address | Building B |
| ZIP | 4672562 |
| Phone | 972 9 799 6183 |
| Website | https://www.neurosense-tx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 17 |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Q&A For NeuroSense Therapeutics Stock
What is a current NRSN stock price?
NeuroSense Therapeutics NRSN stock price today per share is 0.77 USD.
How to purchase NeuroSense Therapeutics stock?
You can buy NRSN shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for NeuroSense Therapeutics?
The stock symbol or ticker of NeuroSense Therapeutics is NRSN.
Which industry does the NeuroSense Therapeutics company belong to?
The NeuroSense Therapeutics industry is Biotechnology.
How many shares does NeuroSense Therapeutics have in circulation?
The max supply of NeuroSense Therapeutics shares is 36.1M.
What is NeuroSense Therapeutics Price to Earnings Ratio (PE Ratio)?
NeuroSense Therapeutics PE Ratio is now.
What was NeuroSense Therapeutics earnings per share over the trailing 12 months (TTM)?
NeuroSense Therapeutics EPS is -0.44 USD over the trailing 12 months.
Which sector does the NeuroSense Therapeutics company belong to?
The NeuroSense Therapeutics sector is Healthcare.
NeuroSense Therapeutics NRSN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}